NK
NKB2.F TG Therapeutics Inc
- Market cap
- EUR 8.92B
- P/E
- 101.7x
- P/B
- 16.94x
- ROE
- 19.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NKB2.F undervalued?
Graham numberThe Graham number of TG Therapeutics Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
TG Therapeutics Inc fundamental analysis
No fundamental analysis for TG Therapeutics Inc yet.
TG Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About TG Therapeutics Inc
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disea…
Full company profileTG Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
TG Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 152K | 152K | 152K | 152K | 152K | 6.69M | 2.79M | 234M | 329M | 616M | 940M |
| Gross Profit | 152K | 152K | 152K | 152K | 152K | 5.90M | 2.52M | 220M | 291M | 516M | 785M |
| Operating Income | -79.0M | -119M | -174M | -169M | -274M | -345M | -193M | 20.6M | 41.9M | 123M | 190M |
| EBITDA | - | -119M | -174M | -167M | -273M | -342M | -188M | 26.1M | 49.9M | 134M | 193M |
| Net Income | -78.3M | -118M | -173M | -173M | -279M | -348M | -198M | 12.7M | 23.4M | 447M | 111M |
| EPS | - | -1.62 | -2.07 | -1.58 | -1.99 | -2.43 | -1.35 | 0.08 | 0.15 | 2.88 | 0.73 |
| Balance Sheet | |||||||||||
| Total Assets | 54.8M | 97.4M | 83.6M | 163M | 626M | 380M | 194M | 330M | 578M | 1.06B | 1.59B |
| Total Liabilities | 18.9M | 30.4M | 59.6M | 124M | 106M | 142M | 135M | 169M | 355M | 415M | 1.02B |
| Shareholders' Equity | 35.9M | 67.0M | 24.0M | 38.6M | 519M | 237M | -1.53B | 161M | 222M | 648M | 572M |
| Cash & Short-term Investments | 25.0M | 56.7M | 42.0M | 113M | 553M | 299M | 102M | 92.9M | 180M | 79.1M | 429M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -61.6M | -93.8M | -129M | -133M | -215M | -296M | -176M | -31.4M | -40.5M | -24.8M | 88.8M |
| Capital Expenditure | 344K | 2.00K | 90.0K | 131K | 357K | 401K | 14.0K | 0.00 | 45.0K | 214K | 835K |
| Free Cash Flow | - | -93.8M | -129M | -133M | -215M | -296M | -176M | -31.4M | -40.6M | -25.0M | 88.0M |
| Ratios | |||||||||||
| ROE | -218.2% | -176.8% | -721.8% | -447.7% | -53.8% | -146.8% | - | 7.9% | 10.5% | 69.0% | 19.3% |
| ROA | -142.8% | -121.7% | -207.5% | -106.0% | -44.7% | -91.7% | -102.5% | 3.8% | 4.0% | 42.1% | 7.0% |
| Net Profit Margin | -51,353.4% | -77,749.9% | -114,132.9% | -113,730.9% | -183,803.3% | -5,204.1% | -7,121.5% | 5.4% | 7.1% | 72.6% | 11.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
TG Therapeutics Inc dividends
TG Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Who owns TG Therapeutics Inc
- Insiders 7.56%
- Institutions 78.79%
- Public & others 13.65%
- Shares outstanding 151M
- Free float 134M
TG Therapeutics Inc company profile
- Company name
- TG Therapeutics Inc
- Ticker
- NKB2.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 399
- Fiscal year end
- December
- Address
- 3020 Carrington Mill Blvd., Morrisville, NC, United States, 27560
- Phone
- 212 554 4484
- Website
- tgtherapeutics.com
About TG Therapeutics Inc
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
TG Therapeutics Inc management
4- Mr. Michael S. Weiss Esq., J.D.Chairman, CEO & President · born 1966
- Mr. Sean A. Power CPACFO, Corporate Secretary & Treasurer · born 1982
- Ms. Jenna BoscoSenior Vice President of Corporate Communications
- Mr. Adam WaldmanChief Commercialization Officer